Showing results (221-230 of 286) with videos related to
Sort By:
Pageof 29
Pediatric Blood & Cancer|July 21, 2006
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)Shana S Jacobs, Linda C Stork, Bruce C Bostrom, et al.British Journal of Haematology|April 22, 2008
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocationBlaine W Robinson, Kathryn C Behling, Manish Gupta, et al.Hospital Pediatrics|December 28, 2019
Structured Chart Review: Assessment of a Structured Chart Review MethodologyAshley Siems, Russell Banks, Richard Holubkov, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2011
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group studySteven G Dubois, Suzanne Shusterman, Ashish M Ingle, et al.Pediatric Blood & Cancer|November 2, 2017
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology GroupRachel E Rau, ZoAnn Dreyer, Mi Rim Choi, et al.Bone|July 25, 2017
Early clinical observations on the use of imatinib mesylate in FOP: A report of seven casesFrederick S Kaplan, Jeffrey R Andolina, Peter C Adamson, et al.Plos One|November 26, 2015
Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology GroupYimei Li, Matt Hall, Brian T Fisher, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Pediatric Blood & Cancer|September 27, 2014
Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I ConsortiumStephan D Voss, Julia Glade-Bender, Sheri L Spunt, et al.Pageof 29